Suprith Badarinath

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 543 citations · Full text

Cobimetinib Versus Regorafenib, Oncology, Medicine +10

Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)

Eric Hedrick, Mark Kozloff, John D. Hainsworth et al. · Journal of Clinical Oncology · 2006 · 87 citations

Progression-free Survival, Surgical Oncology, Cancer Epidemiology +15

Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy

Mary M. Sugrue, Mark Kozloff, John D. Hainsworth et al. · Journal of Clinical Oncology · 2006 · 77 citations

Surgical Oncology, Earlier Gip, Colorectal Surgery +18

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

Leonard B. Saltz, Suprith Badarinath, Shaker R. Dakhil et al. · Clinical Colorectal Cancer · 2011 · 69 citations

Gastrointestinal Oncology, Medicine, Pharmacology +8

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

Kathleen M. Mullane, Vicki A. Morrison, Luis H. Camacho et al. · The Lancet Infectious Diseases · 2019 · 35 citations

Vaccination, Vaccine Safety, Vaccine Development +6